Oppenheimer & Co’s Immunocore IMCR Stock Holding History

Oppenheimer & Co’s Portfolio IMCR Stock Details IMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-14,072	Closed	-$915K	–	1481
2024 Q1	$915K	Sell	14,072 -5,158	-27%	-$354K	0.02%	771
2023 Q4	$1.31M	Buy	+19,230	New	+$1,000K	0.02%	623
2023 Q3	–	Sell	-3,476	Closed	-$208K	–	1420
2023 Q2	$208K	Buy	+3,476	New	+$198K	﹤0.01%	1275
2023 Q1	–	Sell	-6,385	Closed	-$364K	–	1417
2022 Q4	$364K	Buy	+6,385	New	+$359K	0.01%	1021

Other funds holding IMCR

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Oppenheimer & Co's IMCR Position: Q2 2024 in Review

Oppenheimer & Co sold out of Immunocore (IMCR) in Q2 2024, closing a stake of 14,072 shares — an estimated $915K sold.

Oppenheimer & Co first reported a position in IMCR in Q4 2022 and held it in 4 quarters. The position peaked at $1.31M in Q4 2023. 138 funds tracked by Wall St. Rank hold IMCR as of Q2 2024.

Oppenheimer & Co reported no remaining Immunocore position as of Q2 2024 after selling out during the quarter.
Oppenheimer & Co sold 14,072 Immunocore shares in Q2 2024, an estimated $915K.
Oppenheimer & Co first reported a position in Immunocore in Q4 2022 and held it in 4 quarters.
Oppenheimer & Co's Immunocore position peaked at $1.31M in Q4 2023.
138 funds tracked by Wall St. Rank held Immunocore as of Q2 2024.

Based on Oppenheimer & Co's 13F filing for Q2 2024, filed 8 Aug 2024.